PRKD3 and prostate carcinoma: PRKD3 was found to interact with HDAC1 in prostate cancer by suppressing its expression and decreasing its binding to the uPA promotor51, interestingly, HDAC1 is well known to deacetylates p53 and modulates its effect on cell growth and apoptosis, indicating there might be some undiscovered relations between PRKD3 and p53.